LifeArc is calling for applications from academics, NHS employees or companies that have therapeutics that could be repurposed or repositioned for use in COVID-19 patients.
The primary purpose is to accelerate availability of treatments for patients and it is therefore expected that applicants will already have material available for testing and a plan for rapid scale up of clinical material. Priority will be given to projects that have a clear path and availability for patients in a 6-12 month time frame.
LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.
Plans for the structure of the clinical trials should be in advanced stages of development and should follow the specialist guidance from the regulators on COVID-19 trials.
The expectation is that the data obtained will be shared openly and, where knowledge obtained could benefit the development of other COVID-19 therapeutics, this should be done as quickly as is reasonably possible.
Funding Information
The grant will pay for the direct costs of the trials and the science associated with that. There is no official cap on size of applications, however, it is anticipated that a small number of the most promising projects will be funded from the £10M currently available.
Eligibility Criteria
Applications from academics, NHS employees, or companies from any geographical location are welcomed.
Grants will be awarded rapidly under standard, non-negotiable terms. LifeArc will not seek any financial return on these grants. It will not take any equity stakes or other revenue return. It is expected that those receiving funding will respect the spirit of the award and where relevant prioritise COVID-19 patients’ access over any potential for profit.
Applications for funding to supplement existing funding to enable a COVID-19 trial will also be eligible.
Assessment Criteria
Applications will be assessed by an expert scientific and clinical panel to ensure that the key aims of the call are delivered. Applications will be assessed against the following criteria:
Scientific rationale – there must be a clear scientific rationale for why the drug proposed could reasonably be expected to alter the outcome for patients with COVID-19.
Deliverability of the project within an appropriate timescale. As this epidemic is progressing rapidly, applications for projects that can launch quickly, with all the components necessary already available or in an advanced stage of planning, will likely be more competitive e.g:
is the material available or what are the plans for obtaining sufficient clinical quality material?
is there a clinical site already associated with the study and how will the study integrate with the clinical care of these patients?
Trial design – it is important that trials deliver clear meaningful results:
What are the endpoints?
Are the assays available for measuring those endpoints?
Detail on how statistical significance will be assessed and explanation of power calculations should be included in the application?
Are the plans for patient recruitment realistic?
Path to patient – if the trial delivers a positive result how will drug or combination of be made available to patients more widely.
About LifeArc
At LifeArc, They drive medical innovation through their own research and our work with a range of partners from industry, charities, universities, research organisations and others involved in improving lives for patients.
They have a 25-year legacy of collaborating with scientists on diagnostics and therapies, enhancing and protecting innovation and advancing promising research.
They focus on translation – progressing work from early lab-based findings through to development and a point where it can be used in patients. And by working in this way, They play a key role in developing new treatments, medicines, diagnostics, technologies or information resources, and in helping to turn research into practical products that benefit patients.
Post Date - 23-Mar-2020